Sector ratings Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE Other stock markets 16:00:00 2026-07-28 EDT			5-day change	1st Jan Change
2.870 ^USD	+1.77%		-1.71%	+4.36%

07-28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
07-17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PERSPECTIVE THERAPEUTICS, INC.	322M	-	BBB	-	-
LONZA GROUP AG	47.74B		AAA
REVOLUTION MEDICINES, INC.	39.98B	-	B	-	-
BEONE MEDICINES AG	36.23B		-
IQVIA HOLDINGS INC.	35.59B		AAA
CELLTRION, INC.	27.91B		A
ASCENDIS PHARMA A/S	16.71B	-	-	-	-
MEDPACE HOLDINGS, INC.	16.45B		BBB
EUROFINS SCIENTIFIC SE	13.21B		AA
ICON PUBLIC LIMITED COMPANY	12.93B		AAA
BIO-TECHNE CORPORATION	11.16B		AA
ABIVAX	11.1B	-	BBB	-	-
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	10.8B		AA
APOGEE THERAPEUTICS, INC.	10.08B	-	B	-	-
PHARMARON BEIJING CO., LTD.	9.54B		AA
IONIS PHARMACEUTICALS, INC.	9.25B	-	A	-	-
KYMERA THERAPEUTICS, INC.	9.05B	-	BBB	-	-
PRAXIS PRECISION MEDICINES, INC.	8.8B	-	B	-	-
ALKERMES PLC	8.79B		A
PROTAGONIST THERAPEUTICS, INC.	8.72B		BB		-
Average	17.22B		A
Weighted average by Cap.			A